Droperidol for acute psychosis

Area of Science:

• Psychopharmacology
• Emergency Psychiatry
• Clinical Trial Analysis

Background:

• Acute psychotic illnesses, particularly with agitation or violence, often necessitate rapid pharmacological intervention.
• Droperidol, a butyrophenone antipsychotic, is utilized in various countries for emergency sedation and tranquillization.

Purpose of the Study:

• To evaluate the efficacy of droperidol versus alternative treatments for controlling disturbed behavior in acute psychosis.
• To assess droperidol's effectiveness in reducing psychotic symptoms during emergency psychiatric care.

Main Methods:

• Systematic search of multiple electronic databases (e.g., MEDLINE, EMBASE, PsycLIT) and hand searching for randomized clinical trials.
• Inclusion criteria focused on randomized trials comparing droperidol with any intervention for acute psychotic episodes.
• Data extraction and quality assessment were performed, excluding studies with >50% loss to follow-up; risk ratios and confidence intervals were calculated.

Main Results:

• Two relevant randomized trials with usable data were identified; one additional study focused on longer-term outcomes.
• In one trial, droperidol (10mg IV) significantly reduced the need for additional haloperidol injections compared to placebo in the initial minutes (NNT=2).
• Droperidol showed a trend towards reduced need for additional injections compared to haloperidol (5mg IM), with no reported adverse effects in one small trial.

Conclusions:

• The use of droperidol in emergency psychiatric situations is currently supported more by clinical experience than robust randomized trial evidence.
• This critical area of acute psychosis management remains significantly under-researched, highlighting a need for further high-quality clinical trials.